Randomized, double-blind, placebo-controlled study to evaluate the effect of treatment with an SPMs-enriched oil on chronic pain and inflammation, functionality, and quality of life in patients with symptomatic knee osteoarthritis: GAUDI study

Table 2 Pain changes in OA patients according to OMERACT-OARSI (N = 51)

OMERACT-OARSI ⁽¹⁾	Values		P-value
OMERACT-OARSI ⁽¹⁾	SPMs (N = 23)	Placebo (N = 28)	P-value
Constant pain
Mean change from baseline to week 12, % (SD)	− 30.0 (29.10)	− 20.8 (35.48)	0.320 ⁽²⁾
Intermittent pain
Mean change from baseline to week 12, % (SD)	− 30.6 (29.30)	− 18.1 (25.53)	0.019 ⁽³⁾
Total pain
Mean change from baseline to week 12, % (SD)	− 30.7 (28.26)	− 20.7 (26.15)	0.091 ⁽³⁾

Percentage change in each patient has been used to calculate the mean score change
⁽¹⁾ Constant, intermittent, and total scores resulted from the summation of the scores of the individual item answers; changes are shown in percentages; ⁽²⁾ Student's t-test; ⁽³⁾ Mann -Whitney U test
OMERACT-OARSI: Standing Committee for Clinical Trials Response Criteria Initiative and the Outcome Measures in Rheumatology-Osteoarthritis Research Society International; SD: standard deviation; SPMs: specialized pro-resolving lipid mediators

ISSN: 1479-5876